Abstract:
Provided herein are compounds of Formula (I) and pharmaceuticals acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, and prodrugs thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment and/or of an infectious disease (e.g., bacterial infection (e.g., P. aeruginosa infection).
Abstract:
Compuestos derivados de 2-fenil-fluorosulfonamidas de formula (I) donde R 1 , R 2 , R 3 y R 4 son como se definen en la memoria descriptiva y pliego de reivindicaciones; y procedimiento para preparar dichos compuestos al preparar una solución con un agente catalizador de cobre seleccionado de sales de cobre del grupo consistente en: Cu(MeCN)PF 6 , CuOAc, CuBr 2 , CuCl, CuI, Cu(BF 4 )H 2 O o Cu(OSO2CF3)2, una fenantroilina incluyendo neucoproina, bipiridina o fenantrolina como agente quelante de cobre y un solvente orgánico seleccionado del grupo consistente en: MeCN, EToAC, 1,4- dioxano, 1,2-dimetoxietano, MeNO2, Ph-Cl o 1,2- dicloroetano, para luego agregar a la suspensión resultante, Et 3 N•3HF, y luego adicionar estireno sustituido o sin sustituir y Mo(CO) 6 , donde la mezcla resultante es calentada a 70°C hasta producir un gas, agregando posteriormente a la mezcla, gel de sílice, y entonces se deja evaporar el solvente bajo presión reducida, separándose la fluorosulfonamida en una columna cromatográfica.
Abstract:
式(I)(式中、R 1 は置換もしくは非置換のアリールまたは置換もしくは非置換の芳香族複素環基を表し、 R 2 は置換もしくは非置換のアリール、置換もしくは非置換の芳香族複素環基、置換もしくは非置換の脂環式複素環基等を表し、 R 3 は水素原子を表すか、またはR 4 及び隣接する窒素原子と一緒になって置換もしくは非置換の複素環基を形成し、 R 4 は置換もしくは非置換のアリール、置換もしくは非置換の芳香族複素環基、置換もしくは非置換の脂環式複素環基等を表すか、またはR 3 及び隣接する窒素原子と一緒になって置換もしくは非置換の複素環基を形成し、 R 5 、R 6 及びR 7 は、同一または異なって水素原子またはメチルを表す)で表されるペンタジエナミド誘導体またはその薬学的に許容される塩等を提供する。
Abstract translation:公开了由式(I)表示的戊二烯酰胺衍生物或其药学上可接受的盐等。 (I)其中R 1表示取代或未取代的芳基或取代或未取代的芳族杂环基; R 2表示取代或未取代的芳基,取代或未取代的芳族杂环基,取代或未取代的脂环族杂环基等; R 3表示氢原子,或与R 4和R 3相邻的氮原子一起形成取代或未取代的杂环基; R 4表示取代或未取代的芳基,取代或未取代的芳香族杂环基,取代或未取代的脂环族杂环基等,或者与R 3, 与R 4相邻的氮原子形成取代或未取代的杂环基; R 5,R 6和R 7独立地表示氢原子或甲基。
Abstract:
Compounds and methods suppressing aromatase activity expression in cancer cells. Provided are compounds are those of formula I: wherein R1 may be alkyl, cycloakyl, haloalkyl, aryl, substituted aryl, haloaryl, alkoxy, alkylaryl, and arylalkyl; R2 is H, alkyl, aryl, alkylaryl, arylalkyl, and cycloalkyl; R3, with the base nitrogen, forms an amide or sulfonamide; R4 is selected from nitro, amine, amide, and benzamide; or a pharmaceutically acceptable salts thereof. Also provided are small molecule selective aromatase inhibitors having a molecular weight of less 500 g/mol. In some embodiments, the small molecule selective aromatase inhibitors described herein have a molecular weight of less than 450 g/mol. Also provided are methods for suppressing aromatase activity expression in cancer cells comprising the step of administering a pharmaceutically effective amount of a small molecule aromatase inhibitor to a subject in need of such treatment. In one embodiment, the cancer cells are breast cancer cells.
Abstract:
The invention relates to pharmaceutical salts consisting of the active agent tramadol and at least one sugar substitute. The invention also relates to medicaments containing these salts, to the use of these salts for producing medicaments and to forms of administration containing these salts.
Abstract:
The invention relates to oral dosage forms with controlled total-release of an active substance. Said active substance is present in the form of at least two different salts that are present in the dosage form in a solid state of aggregation and that release said active substance in vitro differently.
Abstract:
Novel sulfonylimide and sulfonylmethide compounds are described which are useful as conductive salts. Also described is the use of the above compounds in salt form in battery electrolytes, particular salts having mixed perfluorocarbon and hydrocarbon groups or having all hydrocarbon groups. The above salts are less expensive to produce and still exhibit excellent conductivity and low corrosivity.
Abstract:
This invention relates to new propanolamine derivatives or salts thereof represented by general formula (I), wherein each symbol is as defined in the specification or salts thereof which are beta 3 adrergenic receptor agonists and therefore have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment of diseases indicated in the specification to a human being or an animal.
Abstract:
The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).